About Genomind
Genomind is a Healthcare company based in King Of Prussia (United States) founded in 2009. Genetic tests for personalized mental health treatments are developed. Genomind has raised $64.43 million across 7 funding rounds from investors including SVB, HHS and Claritas Capital. Its chief executive, as recorded, is Bill Brown. Its website genomind.com draws about 64 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Genomind, Inc. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genominds PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.
- Headquarters King Of Prussia, United States
- SectorsHealthcare
- Website category Health · Mental Health
- Email••••••••
- Phone•••• ••••
- Website genomind.com
- Social LinkedIn X Facebook Instagram
- Legal Name Genomind, Inc.
- Total Equity Funding$64.43M (USD)
in 7 rounds
- Latest Funding Round$399.59K (USD), Grant
Sep 2023
- InvestorsSVB
& 2 more
Funding Insights of Genomind
Genomind has successfully raised a total of $64.43M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $399.59 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $64.43M
- Total Rounds 7
- Last Round Grant — $399,593
- First Round $5M
(Apr 2014)
- Investors Count 3
All 7 funding rounds of Genomind with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $399,593 | Grant | – | – | |
| Apr 2021 | $6.4M | Series C | – | – | – |
| Jul 2018 | $20.58M | Series C | – | – | – |
| Jul 2017 | $500,000 | Series C | – | – | – |
| Feb 2017 | $11M | Series C | – | SVB | – |
| Jul 2016 | $20.95M | Series A | – | Claritas Capital | – |
| Apr 2014 | $5M | Series A | – | Claritas Capital | – |
3 investors in total: 3 institutional.
Investors in Genomind
Genomind has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, HHS and Claritas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to early-stage real estate projects. | claritascapital.com | Nashville, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Genomind
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genomind
26 people are tracked at Genomind (11 in leadership, 10 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Bill Brown | CEO | Leadership |
Beverly (Bev) T. | Chief Marketing Officer | Leadership |
David J. Robbins | Chief Scientific Officer | Leadership |
Maria Jose Springer | Chief Operating Officer | Leadership |
Thomas Mahoney | Senior Director of Finance | Leadership |
Allison Fischer | VP Of Marketing | Leadership |
Jackie Newman | VP Client Success- Genomind | Leadership |
Rob Dublin | Chief Administrative Officer | Leadership |
John J. Rushton | Laboratory Director | Leadership |
Dana Schorer | Vice President Of Global Business Development | Leadership |
Chase Pattison | Chief Commercial Officer | Leadership |
David B. Nash | Scientific Advisor | Board & advisors |
Stephen M. Stahl | Scientific Advisor | Board & advisors |
Scott T. Aaronson | Scientific Advisor | Board & advisors |
Stephen V. Faraone | Scientific Advisor | Board & advisors |
Anil Malhotra | Scientific Advisor | Board & advisors |
Roy H. Perlis | Scientific Advisor | Board & advisors |
Mark A. Stein | Scientific Advisor | Board & advisors |
Stephen R. Saklad | Scientific Advisor | Board & advisors |
Kathleen Brady | Scientific Advisor | Board & advisors |
6 more people are available in the full profile.
Complete people profiles for Genomind
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Genomind
3 dated milestones of Genomind across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Genomind is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Grant, of $400K.
Competitors of Genomind
Genomind has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Genomind
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genomind
The website of Genomind (genomind.com) receives about 64.1K visits a month and ranks #547,972 among all websites worldwide, #836 in Mental Health.
- Monthly visits64.1K
▲ 11.5% vs previous month
- Unique visitors22.6K
per month
- Global rank#547,972
among all websites
- Category rank#836
Health · Mental Health
- Bounce rate49%
- Pages per visit2.7
- Average visit1 min 36 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Genomind. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
potomacpsychiatry.com | potomacpsychiatry.com | 100% | #2,303,542 | – | |
| genesight.com | 96% | #224,230 | View details | ||
| clarityxdna.com | 81% | 680.7K | #786,569 | View details | |
mind.org.uk | mind.org.uk | 81% | #38,010 | – | |
| amaehealth.com | 81% | 40K | #716,391 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Genomind
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genomind (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genomind
Complete news archive for Genomind
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomind
Genomind was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Genomind is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Bill Brown is the CEO of Genomind, as recorded in our data.
Genomind is a funded company, having raised a total of $64.43M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Apr 2014.
Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genominds PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.
Genomind's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.
Genomind has 3 investors. Key investors include SVB, HHS, and Claritas Capital.
Genomind operates through Genomind, Inc..